SCHEMBL4476633

SCHEMBL4476633

NC(=O)c1cccc(C(=O)Nc2cccc(C(F)(F)F)c2)c1

nearest known ligand 0.86

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.86
PTGS1 P23219 3/20 0.71
KCNK3 O14649 2/20 0.70
P2RX1 P51575 1/20 0.69
LMNA P02545 1/20 0.69
MEN1 O00255 3/20 0.67
KMT2A Q03164 3/20 0.67
HTT P42858 1/20 0.67
RAB9A P51151 1/20 0.67
KCNK9 Q9NPC2 1/20 0.65
RXFP1 Q9HBX9 2/20 0.64
DDR2 Q16832 1/20 0.64
TSHR P16473 1/20 0.64
PLG P00747 1/20 0.62
PLAU P00749 1/20 0.62
PLAT P00750 1/20 0.62
POLB P06746 1/20 0.62
BTK Q06187 1/20 0.61
LCK P06239 1/20 0.59
TEK Q02763 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31060524 0.94 MAPT (0.76) MAPTPTGS1KCNK3P2RX1LMNA
SCHEMBL4462072 0.94 MAPT (0.76) MAPTPTGS1KCNK3P2RX1LMNA
SCHEMBL4286068 0.90 MAPT (0.94) MAPTPTGS1KCNK3P2RX1LMNA
SCHEMBL3455275 0.89 PLAU (0.71) MAPTPTGS1KCNK3P2RX1LMNA
SCHEMBL6430912 0.89 MAPT (0.81) MAPTPTGS1KCNK3P2RX1LMNA
SCHEMBL6430910 0.87 MAPT (0.70) MAPTPTGS1KCNK3LMNAMEN1
SCHEMBL2493221 0.87 MAPT (0.88) MAPTPTGS1KCNK3P2RX1LMNA
SCHEMBL27942776 0.86 MAPT (0.63) MAPTPTGS1KCNK3P2RX1LMNA
SCHEMBL4463935 0.86 PTGS1 (0.89) MAPTPTGS1KCNK3P2RX1LMNA
SCHEMBL4683413 0.85 KCNK3 (0.88) MAPTPTGS1KCNK3P2RX1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7589101-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2009-09-15 US claimed
US-20080287432-A1 Compounds and Compositions as Protein Kinase Inhibitors IRM LLC (BM) 2008-11-20 US claimed
EP-1928844-A2 BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USE Amgen, Inc (US) 2008-06-11 EP claimed
EP-1919924-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM, LLC (BM) 2008-05-14 EP claimed
WO-2007022268-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2007-02-22 WO claimed
WO-2007022380-A2 BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2007-02-22 WO claimed
US-7589101-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2009-09-15 US disclosed
US-20080287432-A1 Compounds and Compositions as Protein Kinase Inhibitors IRM LLC (BM) 2008-11-20 US disclosed
EP-1919924-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM, LLC (BM) 2008-05-14 EP disclosed
WO-2007022268-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2007-02-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287432-A1 Compounds and Compositions as Protein Kinase Inhibitors AURKC, PTK2B, FRK MAPT 1523/4885PTGS1 3242/4885KCNK3 924/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.